Eli Lilly has launched its oral GLP-1 obesity drug Foundayo (orforglipron) across the U.S., making it available directly to consumers through its LillyDirect cash-pay platform as well as via telehealth providers, pharmacies and digital health services. The once-daily pill, approved by the Food and Drug Administration in April, is designed to support weight loss alongside diet and exercise and marks the first new molecular entity cleared under the regulator’s National Priority Voucher program.
The rollout reflects an aggressive distribution strategy aimed at simplifying access. Patients can obtain the medication through multiple channels, including Amazon Pharmacy, which offers home delivery and expanding same-day service across thousands of locations, as well as through telehealth platforms like Ro and programs such as Weight Watchers Med+. Access is also being supported by GoodRx, which is aligning pricing with discounted cash rates and expanding availability of related treatments like Zepbound QuickPen.
Pricing varies depending on coverage, with commercially insured patients potentially paying as little as $25 per month with savings programs, while self-pay options start at around $149 monthly for lower doses. Medicare Part D users may also gain access at reduced pricing beginning mid-year, broadening affordability across different patient groups.
The launch comes amid intensifying competition with Novo Nordisk in the fast-growing obesity drug market. While Novo previously led with products like Wegovy, Lilly is pushing to expand its market share through wider access, pricing strategies and a direct-to-consumer model. Early data suggests Foundayo can deliver significant weight loss, with patients losing an average of around 27 pounds at higher doses.
By combining a novel oral formulation with broad distribution and flexible pricing, Lilly aims to make weight-loss treatment more accessible while strengthening its position in one of the most competitive areas in pharmaceuticals.
Click here to read the original news story.